SCD News Hub
Newborn sickle cell screening still a challenge, says ICMR: Tribals battle fear, stigma and long journeys
A study by ICMR finds that poor awareness, discrimination and healthcare access gaps continue to delay diagnosis and treatment for children with sickle cell disease.
Read moreSickle Cell Disease hospitalizations in Louisiana parishes
Discover the latest data on sickle cell disease hospitalizations in Louisiana, including statistics by parish and efforts to improve healthcare access.
Read moreOakland hospital receives $1 million for blood disorder research center
UCSF Benioff Children's Hospital Oakland will receive $1.03 million in federal funding to establish a pediatric blood disorder research center focused on sickle cell disease, thalassemia, leukemia and other conditions.
Read moreUS stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy.
Read moreStem cell transplantation found to be more cost-effective than gene therapy for sickle cell disease
Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared with gene therapy and standard of care treatment, according to new research published in Blood .
Read moreFulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns
Shares of Fulcrum Therapeutics plunged 52% on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk concerns raised by the U.S....
Read moreFulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk concerns raised by the U.S. FDA, and explore strategic options including a potential sale or merger.
Read moreFULC Stock Crashes After Hours: What Investors Need To Know
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.
Read moreHigh-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
**media[1081345]**CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206
Read moreHigh-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
/PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE)...
Read more